SUNNYVALE, Calif., Dec. 8 Accuray Incorporated(Nasdaq: ARAY), a global leader in the field of radiosurgery, announced todaythat 150 CyberKnife(R) Robotic Radiosurgery Systems now have been installedworldwide. This milestone was achieved when Hospital Corporation of America(HCA), a leading healthcare services company, installed a CyberKnife System incollaboration with consultant clinician partners at The Harley Street Clinicin London. HCA's addition of this CyberKnife System marks the installation ofits seventh system companywide, including its first outside the United States.
"The combination of the CyberKnife Systems' robotic mobility andintegrated imaging system provides us with a powerful tool for treating tumorswith a precision that wasn't possible before," said Nick Plowman, M.D.,oncologist and clinical director of The CyberKnife Centre London. "TheCyberKnife System not only improves the accuracy with which we can targettumors, but provides the patient with a pain-free experience that minimizesside effects and shortens treatment time."
Availability of the CyberKnife System has grown dramatically, increasingby 50 percent since May 2007 when the company announced that the 100thCyberKnife System was installed at Centre Oscar Lambret in Lille, France.Additionally, patient demand for CyberKnife radiosurgery is on the rise withthe number of patients treated increasing more than 34 percent during fiscalyear 2008. Prostate and lung radiosurgery seem to be driving the demand,having grown approximately 95 percent and 44 percent respectively during thelast fiscal year.
"The rapid growth in deployments of the CyberKnife System around the worldis a testament to the promise of robotic radiosurgery for the treatment of awide variety of tumors," said Euan S. Thomson, Ph.D., president and CEO ofAccuray. "The accuracy and non-invasive nature of CyberKnife radiosurgerygives patients a more convenient and less intrusive option for the treatmentof tumors anywhere in the body."
Currently, HCA has installed CyberKnife Systems in six facilities,including CyberKnife Center of North Florida Radiation Oncology inGainesville, Fla.; CyberKnife Cancer Center at Memorial Hospital inJacksonville, Fla.; St. Lucie Medical CyberKnife Treatment Center in Port St.Lucie, Fla.; Central Florida Regional Hospital in Sanford, Fla.; MenorahMedical Center in Overland Park, Kan.; and Methodist CyberKnife Center in SanAntonio, Texas.
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only roboticradiosurgery system designed to treat tumors anywhere in the bodynon-invasively. Using continual image guidance technology and computercontrolled robotic mobility, the CyberKnife System automatically tracks,detects and corrects for tumor and patient movement in real-time throughoutthe treatment. This enables the CyberKnife System to deliver high-doseradiation with pinpoint precision, which minimizes damage to surroundinghealthy tissue and eliminates the need for invasive head or body stabilizationframes.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is aglobal leader in the field of radiosurgery dedicated to providing an improvedquality of life and a non-surgical treatment option for those diagnosed withcancer. Accuray develops and markets the CyberKnife Robotic RadiosurgerySystem, which extends the benefits of radiosurgery to include extracranialtumors, including those in the spine, lung, prostate, liver and pancreas. Todate, the CyberKnife System has been used to treat more than 50,000 patientsworldwide and currently more than 150 systems have been installed in leadinghospitals in the Americas, Europe and Asia. For more information, pleasevisit http://www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involverisks and uncertainties, including uncertainties associated with the medicaldevice industry. Except for the historical information contained herein, thematters set forth in this press release, including statements relating tocommercialization of products, clinical studies, and regulatory review andapproval are forward-looking statements within the meaning of the "safeharbor" provisions of the Private Securities Litigation Reform Act of 1995.Forward-looking statements speak only as of the date the statements are madeand are based on information available at the time those statements are madeand/or management's good faith belief as of that time with respect to futureevents. You should not put undue reliance on any forward-looking statements.Important factors that could cause actual performance and results to differmaterially from the forward-looking statements we make include: marketacceptance of products; competing products, the combination of our productswith complementary technology; and other risks detailed from time to time byour quarterly reports on Form 10-Q, our Form 12b-25 dated November 7, 2008,our Form 8-K dated November 20, 2008, and our other filings with theSecurities and Exchange Commission. The Company's actual results ofoperations may differ significantly from those contemplated by suchforward-looking statements as a result of these and other factors. We assumeno obligation to update forward-looking statements to reflect actualperformance or results, changes in assumptions or changes in other factorsaffecting forward-looking information, except to the extent required byapplicable securities laws.
SOURCE Accuray Incorporated